Quarter
Charts

Acadia Pharmaceuticals Inc.

ACAD

CIK 0001070494 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$284M
↑+9.4% +$24Mvs FY2024 (Q4)
Operating Income
$17M
↓-88.7% -$136Mvs FY2024 (Q4)
Net Income
$9M
↓-93.7% -$135Mvs FY2024 (Q4)
Gross Profit
$258M
↑+8.4% +$20Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
37/100
  • Profitability
    28ROIC 10.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.83 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    45Asset Turnover 0.78x (1.0+ = capital-efficient)
  • Growth
    48Revenue YoY +9.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin 6.1% · trend -13.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ACAD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$10.64
Total enterprise IV
$1.81B
Diluted shares
0.17B
Terminal PV
$1.31B (72% of total)
Year-5 FCF
$154M
YearProjected FCFDiscounted PV
+1$114M$103M
+2$123M$101M
+3$132M$100M
+4$143M$98M
+5$154M$96M
Terminal$2.11B$1.31B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$5M
investment in PP&E
Stock-based comp (TTM)
$52M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.56B
everything owned
Total liabilities
$337M
everything owed
Stockholders' equity
$1.23B
shareholder claim

Recent performance · 64 quarters

Revenue↑+9.4% +$24M
$284M
Net Income↑+90.3% +$130M
$274M
Free Cash Flow↓-110.0% -$44M
$-4M
Operating Margin↓-53.0pts
6.1%

Drill down

ACAD Sankey

See Acadia Pharmaceuticals Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ACAD Charts

64 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ACAD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics